The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Keytruda meets primary endpoint of OS in HER2-negative gastric cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Topline results from the pivotal phase III KEYNOTE-859 trial investigating Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, were positive. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

Merck and Moderna Inc. have initiated the phase III randomized INTerpath-002 trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Keytruda as adjuvant treatment in patients with completely resected (R0) Stage II, IIIA or IIIB (with nodal involvement [N2]) non-small cell lung cancer. 
Table of Contents

Login

Looking for IP Login?